PACTR202102664354163已完成未知
The Prognosis of Lipid Reprogramming with the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients
ational Cancer Institute Cairo University0 个研究点目标入组 80 人开始时间: 2021年2月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 Year(s) 至 64 Year(s)（—）
- 性别
- Male
入选标准
- •Naïve newly diagnosed with metastatic prostate cancer
- •Age = 50 years
- •No psychological or geographical barriers for regular follow up of the patients.
排除标准
- •Age < 50 years
- •psychological or geographical barriers for regular follow up of the patients.
研究者
相似试验
已完成
4 期
The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer PatientsProstate Cancer MetastaticNCT04776889National Cancer Institute, Egypt70
已完成
不适用
Effect of "lipid metabolism" related genotypes on the treatment response by PUFA add-on therapy for bipolar disorderBipolar disorderJPRN-UMIN000023221Department of Psychiatry, Fujita Health University School of Medicine60
已完成
不适用
Effect of "lipid metabolism" related genotypes on the treatment response by PUFA add-on therapy for bipolar disorder(2)Bipolar DisorderJPRN-UMIN000033503Fujita Health University53
招募中
不适用
Plaque reversal with Early, Aggressive Lipid LoweringatherosclerosisNL-OMON49626Academisch Medisch Centrum60
招募中
不适用
Prospective investigation of clinical, lipidological, vascular and hepatic parameters with regard to cardiovascular risk factors and primary prevention in childhoodDRKS00031182Goethe Universität, Klinikum300